A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 5, 2014, Pages 1089-1098

  Slingerland, Marije ^a   Hess, Dagmar ^b   Clive, Sally ^c   Sharma, Sunil ^d   Sandstrom, Per ^e   Loman, Niklas ^f   Porro, Maria G ^g   Mu, Song ^g   Waldron, Edward ^g   Valera, Sue Zette ^g   Gelderblom, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Klinik für Onkologie und Hämatologie   (Switzerland)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF UTAH   (United States)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Hepatic impairment; Histone; Pan deacetylase inhibitor; Panobinostat; Phase I

Indexed keywords

DRUG METABOLITE; PANOBINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE MARROW; CLINICAL ARTICLE; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; KIDNEY FUNCTION; LIVER DYSFUNCTION; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MODERATE HEPATIC IMPAIRMENT; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; LIVER; LIVER FUNCTION TEST; METABOLIC CLEARANCE RATE; METABOLISM; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; FATIGUE; FEMALE; HUMANS; HYDROXAMIC ACIDS; INDOLES; LIVER; LIVER FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 84922004566     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2594-6     Document Type: Article

References (34)

1. Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280:233-241
2. Atadja PW (2011) HDAC inhibitors and cancer therapy. Prog Drug Res 67:175-195
3. Prince HM, Bishton MJ, Johnstone RW (2009) Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 5:601-612
4. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R et al (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14:4500-4510
5. Rasheed W, Bishton M, Johnstone RW, Prince HM (2008) Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 8:413-432
6. Oki Y, Copeland A, Younes A (2011) Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol 4:245-252
7. Neri P, Bahlis NJ, Lonial S (2012) Panobinostat for the treatment of multiple myeloma. Expert Opin Investig Drugs 21:733-747
8. Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V et al (2013) A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol 161:68-75
9. Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T et al (2009) Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 147:97-101
10. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM et al (2012) Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 30:2197-2203
11. DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T et al (2013) Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 27:1628-1636
12. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C et al (2013) PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122:2331-2337
13. San-Miguel JF, Richardson PG, Gunther A, Sezer O, Siegel D, Blade J et al (2013) Phase ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 31:3696-3703
14. Clive S, Woo MM, Nydam T, Kelly L, Squier M, Kagan M (2012) Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol 70:513-522
15. Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR et al (2012) Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 53:1820-1823
16. Fredenhagen A, Kittelmann M, Oberer L, Kuhn A, Kuhnol J, Delemonte T et al (2012) Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589). Drug Metab Dispos 40:1041-1050
17. National Cancer Institute Organ Dysfunction Working Group (2003) Hepatic dysfunction V3 ed. p 6
18. FDA Guidance for Industry (2003) Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf
19. de Estella-Hermoso MA, Imbuluzqueta I, Campanero MA, Gonzalez D, Vilas-Zornoza A, Agirre X et al (2011) Development and validation of ultra high performance liquid chromatography-mass spectrometry method for LBH589 in mouse plasma and tissues. J Chromatogr B Analyt Technol Biomed Life Sci 879:3490-3496
20. Hollander M, Wolfe DA, Chicken E (2014) Non Parametric Statistical Methods. Wiley, Hoboken, NJ
21. Hodges JL Jr, Lehmann EL (2005) Basic concepts of probability and statistics. Society for industrial and applied mathematics. Holden-Day, San Francisco
22. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181
23. Therasse Patrick, Arbuck Susan G, Eisenhauer Elizabeth A, Wanders Jantien, Kaplan Richard S, Rubinstein Larry et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-214
24. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646-649
25. Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M et al (2010) Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 28:4507-4512
26. Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA et al (2008) Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26:563-569
27. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G et al (2009) Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 27:1800-1805
28. LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI et al (2012) Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res 18:2954-2963
29. Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ et al (2004) Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10:8341-8350
30. Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L et al (2011) Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 68:805-813
31. Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, Xu L et al (2008) Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 36:2355-2370
32. Morita S, Oizumi S, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y et al (2012) Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors. Invest New Drugs 30:1950-1957
33. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F et al (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12:4628-4635
34. Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM (2008) Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J Clin Oncol 26:332-333